rs3816769 — STAT3 STAT3 co-variant

STAT3's Dual Face: When the Common Allele Raises Risk

STAT3¹¹ STAT3
Signal Transducer and Activator of Transcription 3 — a transcription factor that converts cytokine receptor signals (IL-6, IL-10, IL-21, IL-23, and many others) into gene expression changes occupies one of the most contested positions in immunology: it is simultaneously required for anti-inflammatory resolution and for driving the Th17 cell differentiation that underlies autoimmune pathology. This intronic variant at position 42,346,255 on chromosome 17 sits inside STAT3 and has been independently associated with autoimmune thyroid disease, inflammatory bowel disease, psoriasis, and lung cancer across populations spanning New Zealand, Poland, and Turkey. Unusually, the T allele — the majority allele, carried by roughly two thirds of the global population — is the risk variant, while the minority C allele is protective.

The Mechanism

rs3816769 is an intronic variant that does not alter the STAT3 protein sequence directly. The preliminary gene expression data from Domańska et al. (2013) suggest the TT genotype correlates with higher STAT3 transcript levels in non-small cell lung cancer tissue (p=0.0464), which fits the broader biology: elevated STAT3 expression is a double-edged sword. Acute, transient STAT3 activation resolves inflammation by driving IL-10-producing regulatory cells and suppressing NF-κB. But chronic, constitutive STAT3 signaling — the kind that elevated baseline expression could produce — promotes Th17 differentiation, amplifies IL-17 and IL-21 production, sustains autoantibody-promoting follicular helper T cell programs, and drives tumour immune evasion. The rs3816769 intronic position may overlap an enhancer or splicing regulatory element²² enhancer or splicing regulatory element
Intronic regulatory sequences that control transcript isoform ratios or expression magnitude in immune cells that modulates how strongly STAT3 responds to cytokine stimulation. The variant is in strong linkage disequilibrium with rs744166 (another STAT3 intronic variant) and rs1053004, suggesting these SNPs travel together as a haplotype block and may collectively determine STAT3 regulatory output.

The Evidence

The most statistically robust finding comes from Ferguson et al.³³ Ferguson et al.
"Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population," Mutation Research 2010, a case-control study of 302 Crohn's disease patients and 382 controls. The C allele was significantly less frequent in CD patients than in controls (OR=0.71, 95% CI 0.56–0.89, p=0.003), confirming the C allele is protective. Notably, T-allele carriers showed significantly enhanced susceptibility to DNA damage in peripheral blood leukocytes (comet assay), a finding suggesting the variant affects not just immune signalling but genomic stability under inflammatory stress. T-allele carriers also had higher rates of colonic disease location and extra-intestinal manifestations.

In autoimmune thyroid disease, Kotkowska et al.⁴⁴ Kotkowska et al.
"Single nucleotide polymorphisms in the STAT3 gene influence AITD susceptibility, thyroid autoantibody levels, and IL6 and IL17 secretion," Cell Mol Biol Lett 2015 studied 71 AITD patients (39 Hashimoto's thyroiditis, 32 Graves' disease) and 40 controls, finding the C allele and CC genotype significantly over-represented in healthy controls. The CT genotype in Hashimoto's patients was associated with elevated thyroglobulin antibody (TgAb) titres — a direct measure of thyroid autoimmunity severity. The authors also observed that STAT3 genotype influenced ex vivo IL-6 and IL-17 secretion from peripheral blood cells, providing mechanistic support for the epidemiological associations.

In inflammatory bowel disease, Can et al.⁵⁵ Can et al.
"Investigation of IL23R, JAK2, and STAT3 gene polymorphisms in Crohn's disease and ulcerative colitis in a Turkish population," Turkish Journal of Gastroenterology 2016 found rs3816769 associated with Crohn's disease subphenotype and with requirement for immunosuppression in ulcerative colitis — suggesting the variant predicts disease severity beyond initial susceptibility.

A preliminary lung cancer study⁶⁶ preliminary lung cancer study
Domańska et al. 2013, 71 NSCLC patients vs 104 controls — treat as hypothesis-generating until replicated reported TT genotype association with both elevated NSCLC risk and higher tumour STAT3 expression. STAT3 is a well-validated oncogene and the expression correlation (p=0.0464) is biologically plausible, though the small sample warrants independent replication.

Practical Actions

For carriers of one or two T alleles, the actionable insight is about immune surveillance and inflammation monitoring rather than any single drug. Chronically elevated STAT3 signalling promotes Th17-mediated autoimmunity, so the priority is keeping the upstream cytokine environment that activates STAT3 — particularly IL-6, IL-17, and IL-23 — from running unchecked. Long-chain omega-3 fatty acids (EPA+DHA) suppress IL-6 and IL-17 production; adequate vitamin D maintains the T-regulatory/Th17 balance that STAT3 signalling mediates. For TT carriers with established autoimmune thyroid disease or IBD, JAK inhibitors (which block STAT3 phosphorylation) represent mechanistically matched systemic therapy options when standard first-line therapies are insufficient.

Interactions

rs3816769 is in strong LD with rs744166⁷⁷ rs744166
STAT3 intronic variant — associated with IBD, atopic dermatitis, and multiple autoimmune phenotypes across large GWAS studies and rs1053004⁸⁸ rs1053004
STAT3 intronic variant, part of the same haplotype block (r²=0.704 with rs3816769), and is co-listed in research with rs17881320⁹⁹ rs17881320
STAT3 intronic variant associated with atopic dermatitis (OR=1.09 in meta-analysis of 862,032 individuals). Together these STAT3 intronic variants likely form a regulatory haplotype that collectively sets STAT3 expression level and cytokine responsiveness in immune cells. The combined haplotype burden across the STAT3 locus may predict autoimmune risk more powerfully than any single variant.